[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100071772":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":16,"studyPopulation":17,"armGroups":11,"interventions":11,"overallOfficials":18,"centralContacts":22,"locations":33,"responsibleParty":53,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":11,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":11,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The general theme of this core is to investigate the relationship between the virologic response to antiretroviral therapy and clinical outcome.",null,"Ongoing",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. Samples from SCOPE will be used to examine:\n\n1. Virologic, immunologic, and host factors involved in the natural control of HIV-1 infection (long term non-progression and\u002For virologic control of HIV-1 without antiretroviral therapy)\n2. Virologic and immune correlates associated with disease progression\n3. Evolution of antiretroviral drug resistance\n4. Factors associated with transmission or acquisition of HIV infection\n\nEnrolled subjects are seen at San Francisco General Hospital every four months for a detailed interview, saliva collection, and blood draw. Baseline visits take approximately one hour, follow up visits take approximately 20-40 minutes. No personal identifiers are used for specimen bank samples.","The study is open to eligible subjects who are able to perform study visits at San Francisco General Hospital or the San Francisco VA Medical Center.",[19],{"name":20,"affiliation":5,"role":21},"Steven G. Deeks, M.D.","PRINCIPAL_INVESTIGATOR",[23,29],{"name":24,"role":25,"phone":26,"phoneExt":27,"email":28},"Rebecca Hoh, M.S., R.D.","CONTACT","415-476-4082","139","Rebecca.Hoh@ucsf.edu",{"name":30,"role":25,"phone":26,"phoneExt":31,"email":32},"Montha Pao","140","Montha.Pao@ucsf.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"San Francisco General Hospital","RECRUITING","San Francisco","California","94110","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-122.41942,37.77493,{"lat":46,"lon":45},[49,51,52],{"name":50,"role":25,"phone":26,"phoneExt":27,"email":28},"Rebecca Hoh, M.S.",{"name":30,"role":25,"phone":26,"phoneExt":31,"email":32},{"name":20,"role":21,"phone":11,"phoneExt":11,"email":11},{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[56],{"name":57,"class":58},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100071772","scope-observational-study-of-the-consequences-of-the-protease-inhibitor-era-100071772",false,"NCT00187512","SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era","SCOPE","Inclusion Criteria:\n\nSCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:\n\n1. Documented HIV viral load less than 2000 copies\u002Fml WITHOUT taking antiretroviral therapy\n2. Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.\n3. Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.\n4. Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.\n\nExclusion Criteria:\n\n1. Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)\n2. Active treatment for cancer\n3. Active treatment for hepatitis C requiring interferon based therapy\n4. Immunosuppressive therapy taken within the last 4 months","ALL","18 Years",{"count":69,"type":70},2500,"ESTIMATED","OBSERVATIONAL","SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.",[74],"HIV Infections",[76,77,78,79,80,81,82,83,84],"HIV","Antiretroviral Agents","Drug Resistance, Multiple","Long Term Non Progression","Long Term Non Progressor","Elite Suppression","Elite Suppressor","Natural History","Observational","2026-09-04",{"date":87,"type":88},"2026-09-08","ACTUAL",{"date":90,"type":11},"2000-03",{"date":92,"type":70},"2033-12",{"name":5,"class":6},1]